Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria

Ayumi Uchino, Hiroshi Tsukamoto, Hitoshi Nakashima, Seiji Yoshizawa, Isao Furugo, Hiroki Mitoma, Kensuke Oryoji, Terufumi Shimoda, Hiroaki Niiro, Yoshifumi Tada, Takahisa Yano, Toshiharu Nonaka, Ryozo Oishi, Koichi Akashi, Takahiko Horiuchi

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Objectives: To evaluate the safety and potential efficacy of tacrolimus for the treatment of patients with lupus nephritis and persistent proteinuria. Methods: A total of 23 Japanese patients with lupus nephritis (21 females / 2 males) were enrolled in this study. Patients were administered tacrolimus at a dose of 2-3 mg once daily after the evening meal for 6 months. The dose of tacrolimus was unchanged throughout the study period. Concomitant prednisolone therapy was unchanged or gradually tapered, while other immunosuppressants were stopped at the start of tacrolimus treatment. Results: Tacrolimus was well tolerated, and none of the patients developed adverse drug reactions that required discontinuation of the study. Daily urinary protein loss, the U-prot/U-creat ratio, and serum albumin were significantly improved after 4 months, 3 months, and 1 month of treatment with tacrolimus (p<0.05), respectively, and the improvement persisted until 6 months. The serum complement hemolytic activity (CH50), complement C3 level, and CRP level were also significantly improved after treatment with tacrolimus (p<0.05). Improvement of the U-prot/U-creat ratio was most prominent for patients who were in WHO class IV. Conclusion: Tacrolimus is safe and effective as maintenance therapy for patients with lupus nephritis, at least for 6 months. A larger randomised, controlled trial over a longer period is needed to confirm these results.

Original languageEnglish
Pages (from-to)6-12
Number of pages7
JournalClinical and experimental rheumatology
Issue number1
Publication statusPublished - 2010

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria'. Together they form a unique fingerprint.

Cite this